Idorsia Ltd (OTCMKTS:IDRSF) Receives Consensus Recommendation of “Buy” from Analysts

Idorsia Ltd (OTCMKTS:IDRSFGet Rating) has earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $35.00.

Separately, HC Wainwright cut their price target on Idorsia from CHF 41 to CHF 35 and set a “buy” rating on the stock in a research report on Monday, February 14th.

Idorsia stock opened at $17.13 on Friday. Idorsia has a fifty-two week low of $16.85 and a fifty-two week high of $30.12. The stock has a 50-day simple moving average of $19.16 and a 200-day simple moving average of $19.99.

Idorsia Company Profile (Get Rating)

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Read More

Analyst Recommendations for Idorsia (OTCMKTS:IDRSF)

Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.